MARKET

EDSA

EDSA

Edesa Biotech Inc
NASDAQ
1.420
-0.090
-5.96%
After Hours: 1.450 +0.03 +2.11% 18:58 12/31 EST
OPEN
1.490
PREV CLOSE
1.510
HIGH
1.530
LOW
1.410
VOLUME
80.90K
TURNOVER
--
52 WEEK HIGH
4.490
52 WEEK LOW
1.275
MARKET CAP
11.83M
P/E (TTM)
-1.1218
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at EDSA last week (1222-1226)?
Weekly Report · 12/29/2025 09:10
Weekly Report: what happened at EDSA last week (1215-1219)?
Weekly Report · 12/22/2025 09:10
Midday Fly By: Intel eyes SambaNova, Cencora to acquire OneOncology
TipRanks · 12/15/2025 17:01
Weekly Report: what happened at EDSA last week (1208-1212)?
Weekly Report · 12/15/2025 09:11
Edesa Biotech GAAP EPS of -$1.27 beats by $0.51
Seeking Alpha · 12/15/2025 04:38
Edesa Biotech Advances Dermatology and Respiratory Programs in Fiscal 2025
TipRanks · 12/12/2025 22:04
Skin drug developer Edesa Biotech's FY net loss widens to $7.2 mln
Reuters · 12/12/2025 21:36
Edesa Biotech Q4 EPS $(0.32) Misses $(0.27) Estimate
Benzinga · 12/12/2025 21:23
More
About EDSA
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.

Webull offers Edesa Biotech Inc stock information, including NASDAQ: EDSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EDSA stock methods without spending real money on the virtual paper trading platform.